| Ytd | -63.63% | |
| 1y | -74.27% |
| Open | 0.36 | Prev Close | 0.38 | Low | 0.36 | High | 0.38 | Mkt Cap | 11.78M |
| Vol | 23.98K | Avg Vol | 262.69K | EPS | -1.69 | P/E | N/A | Forward P/E | -5.33 |
| Beta | 2.75 | Short Ratio | 3.27 | Inst. Own | 23.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.62 | 200-d Avg | 1.00 | 1yr Est | 12.00 |
SNTI News
Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market s
Senti Biosciences (NASDAQ: SNTI - Get Free Report) will likely be issuing its Q2 2026 results before
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday
Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) ("SBH" or the "Company") today annou
SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NAS
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.14) per share which beat the analys
Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center regis
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center regis
Securities Purchase Agreement On April 27, 2026, Senti Biosciences Holdings, Inc. (the "Company&
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT
Other Events On April 1, 2026, Senti Biosciences, Inc. (the "Company") announced plans to im
Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a clinical-stage biotechnology company
SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.53) per share which missed the anal
SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT
Shares of Senti Biosciences, Inc. (NASDAQ: SNTI - Get Free Report) have received an average rating o
SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT
SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNT
Senti Biosciences, Inc. (NASDAQ: SNTI - Get Free Report) has been given an average rating of "Modera
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable comple
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable comple
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI
Access the segment here
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI
Senti Biosciences, Inc. (NASDAQ: SNTI - Get Free Report) has been given an average recommendation of
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and
Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong
XCUR: 176% | Exicure shares are trading higher after the company announced results from its complete
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patie
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patie
Leerink Partners analyst Jeffrey La Rosa initiates coverage on Senti Biosciences (NASDAQ:SNTI) wi
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.69) per share which missed the anal
Two presentations, including one oral session, build on existing data and show deep and durable clin
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Senti Biosciences (NASDAQ:SNTI
Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.56) per share which beat the analys